Fundamental and clinical studies on cefclidin in complicated urinary tract infections

We studied the antibacterial activity and clinical efficacy of cefclidin (CFCL), a new injectable cephem antibiotic. 1. Antibacterial activity: We determined the MICs of CFCL against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of cefoperazone, latamoxef and ceftazidime. Against Enterococcus faecalis, CFCL had weak antibacterial activity. Against other species, especially Pseudomonas aeruginosa, however, antibacterial activity of CFCL were superior to those of the comparative drugs. 2. Clinical efficacy: Thirty-six patients with complicated urinary tract infection were treated twice a day with 0.5g or 1.0g of CFCL. Out of 36, 28 cases were evaluated according to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 53.6%. Bacteriologically, 38 of 46 strains (82.6%) were eradicated. No side effect were observed. In 3 patients, abnormal laboratory findings were noted, but were not problematic clinically.